Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fosfomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfomycin SCHEMBL3168937 | 1.00 | — | — | |
| Fosfomycin SCHEMBL8633252 | 1.00 | — | — | |
| Fosfomycin SCHEMBL9634477 | 1.00 | — | — | |
| Fosfomycin SCHEMBL10492648 | 1.00 | — | — | |
| Fosfomycin SCHEMBL989825 | 1.00 | — | — | |
| Fosfomycin SCHEMBL50951 | 1.00 | — | — | |
| Fosfomycin SCHEMBL5595663 | 1.00 | LMNA (0.50) | — | |
| Fosfomycin SCHEMBL989824 | 0.97 | — | — | |
| Fosfomycin SCHEMBL9634052 | 0.97 | LMNA (0.48) | — | |
| Fosfomycin SCHEMBL20597804 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5191094-A | Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing | ZAMBON GROUP S.P.A. (IT) | 1993-03-02 | — | — | US | claimed |
| US-5162309-A | Urogenital disorders | ZAMBON GROUP (IT) | 1992-11-10 | — | — | US | claimed |
| EP-0299484-A1 | Process for the preparation of intermediates for the synthesis of fosfomycin | ZAMBON GROUP S.p.A. (IT) | 1989-01-18 | — | — | EP | claimed |
| JP-58134028-A | — | — | None | — | — | JP | disclosed |
| EP-1747781-B1 | STABLE ORAL PHARMACEUTICAL PREPARATION COMPRISING FOSFOMYCIN, WHICH IS INTENDED FOR DIABETIC PATIENTS | SIMBEC IBERICA SL (ES) | 2010-02-17 | — | — | EP | disclosed |
| EP-1762573-A1 | A process for the preparation of fosfomycin salts | Interquim, S.A. De C.V. (MX) | 2007-03-14 | — | — | EP | disclosed |
| EP-1747781-A1 | STABLE ORAL PHARMACEUTICAL PREPARATION COMPRISING FOSFOMYCIN, WHICH IS INTENDED FOR DIABETIC PATIENTS | Simbec Iberica, SL (ES) | 2007-01-31 | — | — | EP | disclosed |
| US-5191094-A | Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing | ZAMBON GROUP S.P.A. (IT) | 1993-03-02 | — | — | US | disclosed |
| US-5191094-A | Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing | ZAMBON GROUP S.P.A. (IT) | 1993-03-02 | — | — | US | disclosed |
| US-5191094-A | Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing | ZAMBON GROUP S.P.A. (IT) | 1993-03-02 | — | — | US | disclosed |
| US-5162309-A | Urogenital disorders | ZAMBON GROUP (IT) | 1992-11-10 | — | — | US | disclosed |
| US-5162309-A | Urogenital disorders | ZAMBON GROUP (IT) | 1992-11-10 | — | — | US | disclosed |
| US-4937367-A | Process for the preparation of intermediates for the synthesis of fosfomycin | ZAMBON GROUP S.P.A. (IT) | 1990-06-26 | — | — | US | disclosed |
| EP-0299484-A1 | Process for the preparation of intermediates for the synthesis of fosfomycin | ZAMBON GROUP S.p.A. (IT) | 1989-01-18 | — | — | EP | disclosed |
| JP-S58134028-A | AGENT FOR MITIGATING OR PREVENTING RENAL TOXICITY OF AMINOGLUCOSIDE ANTIBIOTIC SUBSTANCE | MEIJI SEIKA KAISHA LTD | 1983-08-10 | — | — | JP | disclosed |